Sequenom (NASDAQ:SQNM) Boosted by Validity of 4-plex Sequencing

The release of the study by Dennis Lo on the validity of sequencing is considered a positive by Barclays concerning Sequenom (NASDAQ:SQNM).

Barclays stated, "Dennis Lo's much awaited publication on sequencing for NIPD was published in the British Medical Journal. Top-line results of the paper titled 'Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study' were in line with expectations. We remain Overweight into the read-out from SQNM's own 4-plex sequencing based Locked Assay study."

Barclays reiterates an "Overweight" rating on Sequenom, which closed Thursday at $7.33, down $0.17, or 2.27 percent. Barclays has a price target of $9 on them.